Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy

BACKGROUND: There are currently three coronavirus disease 2019 (COVID-19) vaccines approved by the United States Food and Drug Administration to prevent coronavirus infection. However, robust data are unavailable on the adverse events of the vaccines in patients with solid tumor malignancies undergo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, Ronald E, Parish, Marie, Oxencis, Carolyn, Mckenna, Edward, Thapa, Bicky, Chakrabarti, Sakti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Retrospective Cohort Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346427/
https://www.ncbi.nlm.nih.gov/pubmed/36157156
http://dx.doi.org/10.5306/wjco.v13.i7.599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346427/
https://www.ncbi.nlm.nih.gov/pubmed/36157156
http://dx.doi.org/10.5306/wjco.v13.i7.599

Ejemplares similares